Dose delays and treatment interruptions secondary to ocular toxicity from BMCA-directed antibody drug conjugate therapy in relapsed multiple myeloma
Year: 2025
Type: preprint
Study design: Observational Study
Source: SSRN Electronic Journal
DOI: 10.2139/ssrn.5406682
Authors: Matthew James Rees, Timothy T. Xu, Suheil Albert Atallah-Yunes, Kenneth J. C. Lim, Sikander Ailawadhi, Ricardo Parrondo, Rafael Fonseca, Peter Bergsagel, Suzanne Hayman, Angela Dispenzieri, Francis K. Buadi, David Dingli, Rahma Warsame, Prashant Kapoor, Jithma P. Abeykoon, Morie A. Gertz, Eli Muchtar, Taxiarchis V. Kourelis, Wilson I. Gonsalves, Vincet Rajkumar, Sanjay V. Patel, Shaji K. Kumar
Institutions: Mayo Clinic, New York University
Language: English
Topic: Drug-Induced Ocular Toxicity
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4413751998